Skip to content
Advertisement

This undated photo provided by Merck & Co. shows their new antiviral medication molnupiravir. U.S. regulators have authorized a second pill against COVID-19, an antiviral drug from Merck that may help blunt the wave of infections driven by the omicron variant. The Food and Drug Administration granted the drug emergency use Thursday, Dec. 23, 2021,  for adults with early COVID-19 who face the highest risks of hospitalization. (Merck & Co. via AP, File)

This undated photo provided by Merck & Co. shows their new antiviral medication molnupiravir. U.S. regulators have authorized a second pill against COVID-19, an antiviral drug from Merck that may help blunt the wave of infections driven by the omicron variant. The Food and Drug Administration granted the drug emergency use Thursday, Dec. 23, 2021, for adults with early COVID-19 who face the highest risks of hospitalization. (Merck & Co. via AP, File)

Featured Photo Galleries